EDITOR'S DESK

Sterile Injectable Outsourcing Trends: What Biosimilar Developers Must Know

Though a majority of the data points in a recent ISR report on Sterile Manufacturing are not specifically focused around biosimilars, I reached out to the report’s lead author to unpack a handful of findings I thought would be important for those involved in both biologics and biosimilar manufacturing and outsourcing.  

Solving Pharma’s Public Opinion Crisis

Americans' view of the pharma industry is at an all-time low. NSF Health Sciences Global VP Martin Lush says to change that, something radical will have to happen.

Why EU’s New Med Device Regs Matter To Biopharma

Pharma's CMC regulatory affairs staff, R&D leadership, manufacturing, quality and compliance professionals take note: the EU MDR is real, it becomes effective next May, and it brings with it new challenges and regulatory uncertainty for manufacturers of combination products.     

FDA’s Woodcock: Biosimilar Development Promotes Future Of Better Biologics

While some regulators may express skepticism that we’ll see major changes to the clinical component of the biosimilar development pathway, Woodcock’s DIA keynote exemplified what I found to be a strikingly different attitude about the future possibilities for biosimilar development.

More From Our Editors

GUEST COLUMNISTS

  • Sampling And Testing Of ATMPs: Gaining Insights From PIC/S Annex 2A
    Sampling And Testing Of ATMPs: Gaining Insights From PIC/S Annex 2A

    With minimal specific guidance on commercial manufacturing from the FDA and a lack of robust platform commercial processes, some of the finer details of cell and therapy manufacturing can make operating companies feel like they are walking on a precarious limb.

  • Biosimilars: Lessons Learned From Regulatory Approvals
    Biosimilars: Lessons Learned From Regulatory Approvals

    The EU has approved 16 biological molecules, and the U.S. has licensed the same molecules (including approving some as 505(b)(2) approvals), except for follitropin alfa, which amounts to 114 biosimilars, combined. This article, based on the EMA’s European public assessment reports (EPARs) and the FDA’s BLA (biologics license application) reviews, identifies many inconsistencies that require revision of regulatory guidance to assure faster approval of biosimilars.

  • Drug Coupons: An Ongoing Debate Between States, Payers, And Manufacturers
    Drug Coupons: An Ongoing Debate Between States, Payers, And Manufacturers

    The clock is ticking for state lawmakers to preserve an existing law that allows for prescription drug coupon usage in Massachusetts with an end-of-the-year deadline fast approaching. Drug manufacturers are anxiously awaiting this legislative action, as a ban on coupons would stick consumers with more of the cost when purchasing brand name drugs, which typically come with higher cost-sharing than generic equivalents.

  • Improve Packaging Line Efficiency Through Overall Equipment Effectiveness
    Improve Packaging Line Efficiency Through Overall Equipment Effectiveness

    This article focuses on efficiency initiatives, providing some insights on how to better use overall equipment effectiveness (OEE) tracking systems and how to avoid common mistakes.

  • Can The FDA Salvage Interchangeable Follow-On Biologics?
    Can The FDA Salvage Interchangeable Follow-On Biologics?

    Learn the statutory and regulatory requirements for interchangeability designation, how the designation hampers follow-on biologics, and why the FDA should loosen requirements for the designation.

  • Process Characterization: The Foundation For Validation
    Process Characterization: The Foundation For Validation

    Process characterization is the foundation for process validation activities. Too often, validation activities fail due to the lack of process characterization using sound statistical and scientific methods, including design of experiments (DOE).

  • People: The Most Persistent Risk To Data Integrity
    People: The Most Persistent Risk To Data Integrity

    HR changes continually impact overall data integrity—from a single new hire to a corporate-level change with a merger or acquisition. It's a commonly overlooked weak link in the data integrity chain.

  • Pigeons In The Plant: 10 Real-Life Pharma Facility Blunders (And How To Avoid Them)
    Pigeons In The Plant: 10 Real-Life Pharma Facility Blunders (And How To Avoid Them)

    There are situations we have come across where we really scratch our heads and say, “What did they just do, and what were they thinking?” This article describes a series of events and activities that we have seen that are at once amusing, baffling, and revealing of the flaws in our industry.

More From Our Guest Columnists

BIOPROCESSING WHITE PAPERS

  • Optimizing Process Efficiency In Upstream Manufacturing

    Increasing the integration of upstream and downstream processing and moving toward increased automation results in greater optimization of process efficiency — a key goal for biopharma production.

  • More Efficient Bispecific Antibody Purification With Fewer Steps

    A single-step downstream process using protein A chromatography to purify a bispecific antibody (BsAb) in early screening has been successfully developed to replace an existing-three step process.

  • A Highly Reproducible In Vivo Model For Bleomycin-Induced Lung Fibrosis In Mice To Evaluate Drugs For The Treatment Of IPF

    Bleomycin-induced pulmonary fibrosis has been a useful pre-clinical model in several species and is most prevalent in rodent models to evaluate potential prophylactic and therapeutic drugs for IPF. The induction and progression of the disease in rodents is of a short duration, making it a practical model for evaluating test compounds in preclinical research. Major drawbacks for this model have been its mortality rate and inconsistency in the induction of the disease. Access to a large portfolio of in vivo fibrosis models allowed for successful drug testing.

  • The Golden Retriever Lifetime Study: 5 Years Of Progress In Veterinary Health And Biobanking

    This whitepaper is an overview of a prospective cohort study of approximately 3,000 Golden Retrievers under the age of 2 years at enrollment and how the extensive data and biological sample repositories will be used for future analyses of major diseases, disorders or conditions in Golden Retrievers.

  • Considerations For Upstream Biologic Development

    The path from DNA to clinic to drug-in-vial is long and complex, and choices made during upstream development can strongly influence the success of a biologic candidate. These considerations might simplify and improve the economics of the process, helping molecules get to market as quickly as possible.

More Bioprocessing White Papers

BIOPROCESS ONLINE CONTENT COLLECTIONS

DataIntegrity

 

This free collection of articles is from the Data Integrity In The Life Sciences series, the purpose of which is to highlight contemporary insights and relationships to key quality systems in order to elevate the most important topics and advance improvements in the collective quality culture.

More Content Collections

LIFE SCIENCE INDUSTRY EVENTS

Essentials of Disinfectant Efficacy Testing – Ensuring Microbial Control December 12 - 12, 2019
1pm-2:30pm EST, Online Training
Effective Batch Record Review – Getting It Right The First Time January 8 - 8, 2020
1:00pm - 2:30pm EST, Online Training
Clinical Research Project Management - 7 Breakthrough Behaviors For Success January 14 - 14, 2020
1pm-2:30pm EDT, Online Training
Understanding Aseptic Technique and Cleanroom Behavior – Avoiding Human Error January 15 - 15, 2020
1pm-2:30pm EST, Online Training
More Industry Events

TRAINING COURSES

Essentials of Disinfectant Efficacy Testing – Ensuring Microbial Control December 12 - 12, 2019
1pm-2:30pm EST, Online Training
Effective Batch Record Review – Getting It Right The First Time January 8 - 8, 2020
1:00pm - 2:30pm EST, Online Training
Clinical Research Project Management - 7 Breakthrough Behaviors For Success January 14 - 14, 2020
1pm-2:30pm EDT, Online Training
Understanding Aseptic Technique and Cleanroom Behavior – Avoiding Human Error January 15 - 15, 2020
1pm-2:30pm EST, Online Training
More Upcoming Courses